Key Facts on Healthcare Stocks Innovating with AI
Investors are eyeing Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Intuitive Surgical (NASDAQ: ISRG) for their potential to leverage artificial intelligence (AI) in healthcare. Eli Lilly is collaborating with Nvidia to build a supercomputer aimed at reducing the drug discovery phase, currently costing over $2.8 billion and taking up to six years. AI could potentially shorten this timeline by one to two years, resulting in significant cost savings and enhanced research capabilities.
Novo Nordisk is partnering with OpenAI to enhance various aspects of its drug development process, particularly in obesity and diabetes treatments. The company’s promising drug candidate UBT251 aims to mimic three gut hormones, showing significant efficacy potential compared to existing treatments. Intuitive Surgical leads the robotic-assisted surgery market and is utilizing AI to harness data from thousands of procedures, aiming to enhance the safety and effectiveness of its da Vinci surgical system.
These companies are positioned to capitalize on the evolving landscape of AI in healthcare, which shows a growing importance across diverse sectors beyond traditional technology.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
